#biopharma — Public Fediverse posts

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AstraZeneca to pay Pfizer $107.5M in damages in Tagrisso patent tussle—FDA approves two biosimilars to blockbuster eye drug Eylea —Why AlphaFold 3 is stirring up so much buzz in pharma --http://bit.ly/w28kSd #astrazeneca #pfizer #patents #legal #biosimilars #fda #eylea #ai #googledeepmind #drugdevelopment #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AstraZeneca to pay Pfizer $107.5M in damages in Tagrisso patent tussle—FDA approves two biosimilars to blockbuster eye drug Eylea —Why AlphaFold 3 is stirring up so much buzz in pharma --http://bit.ly/w28kSd #astrazeneca #pfizer #patents #legal #biosimilars #fda #eylea #ai #googledeepmind #drugdevelopment #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AstraZeneca to pay Pfizer $107.5M in damages in Tagrisso patent tussle—FDA approves two biosimilars to blockbuster eye drug Eylea —Why AlphaFold 3 is stirring up so much buzz in pharma --http://bit.ly/w28kSd #astrazeneca #pfizer #patents #legal #biosimilars #fda #eylea #ai #googledeepmind #drugdevelopment #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

5 successful phase III oncology trials in Q1—FDA gives nod to BrainStorm for ALS trial after Phase III flop—AbbVie’s Humira loses only 4% of market share to biosimilars--http://bit.ly/w28kSd #clinicaltrials #oncology #fda #als #abbvie #humira #biosimilars #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Could pharma’s legal attack on the IRA succeed in killing price negotiations?—Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab—Sandoz nabs FDA approvals for first two biosimilars for Amgen’s denosumab--http://bit.ly/w28kSd #inflationreductionact #medicare #drugpricing #gileadsciences #sandoz #biosimilars #amgen #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Could pharma’s legal attack on the IRA succeed in killing price negotiations?—Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab—Sandoz nabs FDA approvals for first two biosimilars for Amgen’s denosumab--http://bit.ly/w28kSd #inflationreductionact #medicare #drugpricing #gileadsciences #sandoz #biosimilars #amgen #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna posts surprise quarterly profit as it eyes RSV vaccine approval —Samsung joins biosimilar race for Merck & Co.'s Keytruda blockbuster—Zimmer receives FDA clearance for robotic shoulder system--http://bit.ly/w28kSd #moderna #rsv #vaccines #merck #samsung #biosimilars #keytruda #roboticsurgery #zimmerbiomet #fda #shoulderreplacement #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie’s Humira maintains market dominance amid biosimilar launches —Bayer CEO Bill Anderson makes his mark with major restructuring, 'significant' job cuts — Novartis ends phase III peanut allergy trial --http://bit.ly/w28kSd #biosimilars #humira #abbvie #bayer #restructuring #layoffs #novartis #clinicaltrials #peanutallergy #novartis #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck drops up to $610M on neuro disease-focused Caraway Therapeutics -- AstraZeneca’s Imfinzi Phase III trial raises trial design questions --Teva granted pretrial appeal in high-stakes Copaxone kickbacks case-- See more on our front page news http://bit.ly/w28kSd #merck #mergersandacquisitions #astrazeneca #imfinzi #clinicaltrials #tevapharm #copaxone #kickbacks #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

FDA puts Innate's lymphoma trials on partial hold after patient death -- Scientists want to put carbon footprints on drugs -- At Viatris' request, US agency will review another Novo Nordisk patent on semaglutide -- See more on our front page news http://bit.ly/w28kSd #fda #clinicaltrials #lymphoma #carbonfootprint #sustainability #viatris #novonordisk #semaglutide #generics #ozempic #wegovy #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result — Madrigal shares triple on positive NASH study results — Congress passes bill to rein in conflicts of interest for consultants such as McKinsey -- See more on our front page news http://bit.ly/w28kSd #imfinzi #astrazeneca #clinicaltrials #nash #congress #mckinsey #consultants #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma